-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA Grants Priority Review To Takeda's Oveporexton (TAK-861) For Narcolepsy Type 1, Targeting First-In-Class Orexin Therapy

Benzinga·02/10/2026 08:42:05
Listen to the news
  • This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment Options
  • Oveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1
  • The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year